Stocks that traded heavily or had substantial price changes Monday:
Pfizer Inc., up $1.21 to $49.93.
The Food and Drug Administration gave full approval to the COVID-19 vaccine the company developed with BioNTech.
Trillium Therapeutics Inc., up $11.50 to $17.59.
The developer of cancer treatments agreed to be acquired by Pfizer for more than $2 billion in cash.
DoorDash Inc., down $1 to $183.08.
A California judge struck down a ballot measure exempting app-based delivery and ride-hailing services from a law requiring drivers to be classified as employees.
General Motors Co., down 62 cents to $48.18.
The automaker is recalling all Chevrolet Bolt electric vehicles worldwide to fix a battery problem that could cause fires.
Madison Square Garden Entertainment Corp., up $10.12 to $72.55.
The company reported revenue that was higher than analysts were expecting as its venues resumed hosting live events.
Analog Devices Inc., up $2.99 to $169.63.
The chipmaker received antitrust clearance from Chinese regulators for its combination with Maxim Integrated Products.
Occidental Petroleum Corp., up $1.52 to $23.47.
Energy companies were broadly higher as crude oil prices regained some of the ground lost in recent days.
Lennar Corp., down 87 cents to $104.45.
Homebuilders were lower following a report that sales of previously occupied homes rose at a more moderate pace in July from a year ago.
Before you consider Trillium Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trillium Therapeutics wasn't on the list.
While Trillium Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
